Drug intelligence / Profile preview

KT095

Development stage: Phase 1
Lead developer: Nanjing Kati Medical Technology
Modality: Small Molecules
Administration: Intravenous

Overview

KT095 is a synthesized opioid derivative that functions as a kappa-opioid receptor agonist and mu- and delta-opioid receptor antagonist. It has demonstrated analgesic properties and has been investigated for its effects on learning and memory. Developed by Nanjing Kati Medical Technology Co., Ltd., this small molecule is currently in preclinical development.

Other names: 3-acetoxy-6beta-acetylthio-10-oxo-N-cyclopropylmethyl-dihydronormorphine

Targets

KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on KT095.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KT095.

Explore the full profile